Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultragentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results ...

While laser hair removal has proven to be effective in permanently removing hair, it can be associated with the release of a plume that contains airborne particles and hazardous organic compounds, which if inhaled may affect the short and long term health of professional providing the treatments. At present, well over a dozen states have enacted legislation mandating the use of plume evacuation systems in order to mitigate the hazards and risks of exposure to the plume. Adam Levy, CEO of NEXGEL, commented, ...

Forward-Looking Statement NEXGEL and Vanalay have initiated a human trial being conducted at the Florida Clinical Research Center by plastic surgeons, Dr. Barry DiBernardo of New Jersey Plastic Surgery and Dr. Jason Pozner of Sanctuary Medical Aesthetic Center in Fort Lauderdale, Florida. NEXGEL's hydrogel will be applied to 30 patients prior to laser hair removal treatments with the primary outcome measure being the reduction of plume in the air during these procedures. NEXGEL and Vanalay expect top-line d ...

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024. Based on preliminary and unaudited review, the Company anticipates: Second Quarter 2024 Re ...

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024. Based on preliminary and unaudited review, the Company anticipates: Second Quarter 2024 Re ...

Company Overview - NEXGEL Inc is a leading provider of medical and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications [1] - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [2] - NEXGEL's product portfolio includes brands such as Silverseal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George® [2] - The company maintains strategic contract manufacturing relationships with leading consumer healthcare companies [2] Partnership Announcement - NEXGEL has entered into a supply agreement with Cintas Corporation, a Fortune 500 company serving over 1 million businesses across North America [1][4] - Under this agreement, NEXGEL will supply its SilverSeal product to Cintas for distribution to customers in various sectors including hospitality and public service [6] - The first order of SilverSeal is expected to be delivered in Q4 2024 [6] Product Details - SilverSeal is a hospital-grade hydrogel dressing designed for wound and burn care [6] - The product will be offered as a wound care solution for employees of Cintas' customers [6] Strategic Significance - The partnership with Cintas is significant for NEXGEL due to both revenue potential and brand awareness for SilverSeal [4] - Cintas is a major provider of products and services that help businesses maintain clean, safe, and professional environments [4] Market Position - Cintas Corporation is a publicly traded company on the Nasdaq Global Select Market under the symbol CTAS [4] - The company is a component of both the S&P 500 Index and Nasdaq-100 Index [4]

About STADA Arzneimittel AG Forward-Looking Statement preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may ca ...

Core Insights - NEXGEL, Inc. has announced the distribution of Histasolv®, a leading DAO enzyme supplement in Europe, through its partnership with STADA Arzneimittel AG, targeting the North American market [1][7] - Histasolv® generates over $10 million in annualized revenue and is designed to treat histamine food intolerance, which can lead to various health issues [1][2] - STADA is a prominent player in consumer healthcare, achieving group sales of EUR 3,797.2 million and EBITDA of EUR 884.7 million in 2022 [4] Product Differentiation - Histasolv® features an innovative formulation that allows it to deliver high potency DAO to the lower intestine, enhancing its effectiveness compared to competitors [2] - The product is individually sealed in nitrogen-preserved blister packs, ensuring stability and potency [2] Strategic Partnership - The partnership between NEXGEL and STADA aims to leverage STADA's expertise in histamine management to penetrate the North American market [3][8] - NEXGEL plans to sell Histasolv® direct-to-consumer starting in the third quarter of 2024, aligning with its strategy to disrupt the traditional consumer health industry [2][7] Company Background - NEXGEL specializes in high-water-content hydrogels for healthcare and consumer applications, with a portfolio that includes brands like Silverseal® and Hexagels® [3] - STADA operates under a three-pillar strategy focusing on consumer healthcare products, generics, and specialty pharmaceuticals, with a presence in approximately 120 countries [4]

NEXGEL has acquired all of the assets of Silly George for $400,000 in cash, $200,000 in NEXGEL common stock, and a 4-year net profit earn out. Under the terms of the agreement, management of Silly George will remain in place and inventory will be provided by the seller at cost and paid for after the sale of each unit. Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE ...

Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George, an international beauty company with specialty in eye and eyelash consumer products ...